東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Intellectual property rights in phar...

Buick, Adam.

FindBook

Google Book

Amazon

博客來

Intellectual property rights in pharmaceutical test data = origins, globalisation and impact /

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Intellectual property rights in pharmaceutical test data/ by Adam Buick.
其他題名:	origins, globalisation and impact /
作者:	Buick, Adam.
出版者:	Cham :Springer International Publishing : : 2023.,
面頁冊數:	1 online resource (xvi, 227 p.) :ill., digital ;24 cm.
內容註:	Chapter 1 - Introduction -- Chapter 2 - An overview of the protection of submitted test data -- Chapter 3 - The origins of test data exclusivity -- Chapter 4 - The protection of submitted test data and the TRIPS Agreement -- Chapter 5 - The globalisation of test data exclusivity -- Chapter 6 - Approaches to the Implementation of the Protection of Submitted Test Data -- Chapter 7 - The impact of test data exclusivity -- Chapter 8 - The Impact of Test Data Exclusivity on Measures for the Protection of Public Health -- Chapter 9 - Conclusion.
Contained By:	Springer Nature eBook
標題:	Intellectual property (International law) -
電子資源:	https://doi.org/10.1007/978-3-031-29436-5
ISBN:	9783031294365

Intellectual property rights in pharmaceutical test data = origins, globalisation and impact /
Buick, Adam.

Intellectual property rights in pharmaceutical test dataorigins, globalisation and impact /[electronic resource] :by Adam Buick. - Cham :Springer International Publishing :2023. - 1 online resource (xvi, 227 p.) :ill., digital ;24 cm.

Chapter 1 - Introduction -- Chapter 2 - An overview of the protection of submitted test data -- Chapter 3 - The origins of test data exclusivity -- Chapter 4 - The protection of submitted test data and the TRIPS Agreement -- Chapter 5 - The globalisation of test data exclusivity -- Chapter 6 - Approaches to the Implementation of the Protection of Submitted Test Data -- Chapter 7 - The impact of test data exclusivity -- Chapter 8 - The Impact of Test Data Exclusivity on Measures for the Protection of Public Health -- Chapter 9 - Conclusion.

This book considers the intellectual property protection of clinical test data that has been submitted to governments, in particular through test data exclusivity rights. It focuses on how these intellectual property rights first emerged in the early 1980s, how they have globalised over the past four decades, and what impact they have had upon access to medicine. This book makes a number of significant and original contributions to the literature around the protection of submitted test data. First, the book draws upon the theory of regulatory globalisation to provide an explanation of how intellectual property rights in submitted pharmaceutical test data have become nearly ubiquitous in the legal systems of most major economies. Second, through a comprehensive analysis and synthesis of provisions on the protection of submitted test data in free trade agreements, as well as a comparison of a range of national approaches to the protection of submitted test data, it reveals the broader global regulatory pattern that has given rise to these intellectual property rights. Third, by analysing data on drug approvals in the US, it provides an empirical insight into the impact of test data exclusivity in national pharmaceutical markets. Fourth, the book covers a number of developments regarding test data exclusivity that have occurred as a result of responses to the COVID-19 pandemic, both at the national level as well as at the World Trade Organisation (WTO) This book will appeal to academics researching the intersection of intellectual property and the life sciences, civil society activists working to promote access to medicines, and students (particularly those at the post-graduate level) studying the relationship between intellectual property and medicine.

ISBN: 9783031294365

Standard No.: 10.1007/978-3-031-29436-5doiSubjects--Topical Terms:

596623
Intellectual property (International law)

LC Class. No.: K1401

Dewey Class. No.: 346.048

Intellectual property rights in pharmaceutical test data = origins, globalisation and impact /
LDR:03342nmm a2200325 a 4500 001 2318921
003 DE-He213
005 20230512141948.0
006 m d
007 cr nn 008maaau
008 230902s2023 sz s 0 eng d
020 $a 9783031294365 $q (electronic bk.)
020 $a 9783031294358 $q (paper)
024 7 $a 10.1007/978-3-031-29436-5 $2 doi
035 $a 978-3-031-29436-5
040 $a GP $c GP
041 0 $a eng
050 4 $a K1401
072 7 $a LNJ $2 bicssc
072 7 $a LAW000000 $2 bisacsh
072 7 $a LNJ $2 thema
082 0 4 $a 346.048 $2 23
090 $a K1401 $b .B932 2023
100 1 $a Buick, Adam. $3 3634388
245 1 0 $a Intellectual property rights in pharmaceutical test data $h [electronic resource] : $b origins, globalisation and impact / $c by Adam Buick.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2023.
300 $a 1 online resource (xvi, 227 p.) : $b ill., digital ; $c 24 cm.
505 0 $a Chapter 1 - Introduction -- Chapter 2 - An overview of the protection of submitted test data -- Chapter 3 - The origins of test data exclusivity -- Chapter 4 - The protection of submitted test data and the TRIPS Agreement -- Chapter 5 - The globalisation of test data exclusivity -- Chapter 6 - Approaches to the Implementation of the Protection of Submitted Test Data -- Chapter 7 - The impact of test data exclusivity -- Chapter 8 - The Impact of Test Data Exclusivity on Measures for the Protection of Public Health -- Chapter 9 - Conclusion.
520 $a This book considers the intellectual property protection of clinical test data that has been submitted to governments, in particular through test data exclusivity rights. It focuses on how these intellectual property rights first emerged in the early 1980s, how they have globalised over the past four decades, and what impact they have had upon access to medicine. This book makes a number of significant and original contributions to the literature around the protection of submitted test data. First, the book draws upon the theory of regulatory globalisation to provide an explanation of how intellectual property rights in submitted pharmaceutical test data have become nearly ubiquitous in the legal systems of most major economies. Second, through a comprehensive analysis and synthesis of provisions on the protection of submitted test data in free trade agreements, as well as a comparison of a range of national approaches to the protection of submitted test data, it reveals the broader global regulatory pattern that has given rise to these intellectual property rights. Third, by analysing data on drug approvals in the US, it provides an empirical insight into the impact of test data exclusivity in national pharmaceutical markets. Fourth, the book covers a number of developments regarding test data exclusivity that have occurred as a result of responses to the COVID-19 pandemic, both at the national level as well as at the World Trade Organisation (WTO) This book will appeal to academics researching the intersection of intellectual property and the life sciences, civil society activists working to promote access to medicines, and students (particularly those at the post-graduate level) studying the relationship between intellectual property and medicine.
650 0 $a Intellectual property (International law) $3 596623
650 0 $a Drugs $x Testing5 $x Data processing $x Law and legislation. $3 3634389
650 0 $a Medical laws and legislation. $3 783176
650 1 4 $a IT Law, Media Law, Intellectual Property. $3 3384747
650 2 4 $a Medical Law. $3 897066
650 2 4 $a Biomedical Research. $3 851895
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer Nature eBook
856 4 0 $u https://doi.org/10.1007/978-3-031-29436-5
950 $a Law and Criminology (SpringerNature-41177)